JP2004262930A - α−グルコシダーゼ阻害剤 - Google Patents
α−グルコシダーゼ阻害剤 Download PDFInfo
- Publication number
- JP2004262930A JP2004262930A JP2004034321A JP2004034321A JP2004262930A JP 2004262930 A JP2004262930 A JP 2004262930A JP 2004034321 A JP2004034321 A JP 2004034321A JP 2004034321 A JP2004034321 A JP 2004034321A JP 2004262930 A JP2004262930 A JP 2004262930A
- Authority
- JP
- Japan
- Prior art keywords
- glucosidase
- obesity
- glucosidase inhibitor
- diabetes
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 title claims abstract description 15
- 239000003888 alpha glucosidase inhibitor Substances 0.000 title claims abstract description 15
- 208000008589 Obesity Diseases 0.000 claims abstract description 14
- 235000020824 obesity Nutrition 0.000 claims abstract description 14
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 4
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 4
- 235000008434 ginseng Nutrition 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 3
- 241000208340 Araliaceae Species 0.000 claims 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 abstract description 9
- 108010028144 alpha-Glucosidases Proteins 0.000 abstract description 9
- 230000000694 effects Effects 0.000 abstract description 9
- 201000001421 hyperglycemia Diseases 0.000 abstract description 4
- 102000004190 Enzymes Human genes 0.000 abstract description 3
- 108090000790 Enzymes Proteins 0.000 abstract description 3
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 102000004366 Glucosidases Human genes 0.000 abstract 1
- 108010056771 Glucosidases Proteins 0.000 abstract 1
- 230000015556 catabolic process Effects 0.000 abstract 1
- 230000003197 catalytic effect Effects 0.000 abstract 1
- 238000006731 degradation reaction Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000000979 retarding effect Effects 0.000 abstract 1
- 239000000284 extract Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 13
- 239000008280 blood Substances 0.000 description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 239000003814 drug Substances 0.000 description 10
- 229940079593 drug Drugs 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 9
- 229930006000 Sucrose Natural products 0.000 description 6
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 150000001720 carbohydrates Chemical group 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 235000016623 Fragaria vesca Nutrition 0.000 description 3
- 240000009088 Fragaria x ananassa Species 0.000 description 3
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 3
- 241000208422 Rhododendron Species 0.000 description 3
- 235000004789 Rosa xanthina Nutrition 0.000 description 3
- 241000220222 Rosaceae Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 235000019577 caloric intake Nutrition 0.000 description 3
- -1 defoamers Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 230000000225 effect on diabetes Effects 0.000 description 2
- 230000000062 effect on obesity Effects 0.000 description 2
- 238000009207 exercise therapy Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 1
- JMGCAHRKIVCLFW-UHFFFAOYSA-N 1-O-Galloylcastalagin Natural products Oc1cc(cc(O)c1O)C(=O)OC2C3OC(=O)c4c2c(O)c(O)c(O)c4c5c(O)c(O)c(O)c6c5C(=O)OC3C7OC(=O)c8cc(O)c(O)c(O)c8c9c(O)c(O)c(O)cc9C(=O)OCC7OC(=O)c%10cc(O)c(O)c(O)c6%10 JMGCAHRKIVCLFW-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 1
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000061508 Eriobotrya japonica Species 0.000 description 1
- 235000009008 Eriobotrya japonica Nutrition 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 241000193385 Geobacillus stearothermophilus Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 241001243666 Photinia serratifolia Species 0.000 description 1
- 240000008474 Pimenta dioica Species 0.000 description 1
- 235000006990 Pimenta dioica Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 1
- 244000223014 Syzygium aromaticum Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960002632 acarbose Drugs 0.000 description 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- JMGCAHRKIVCLFW-CNWXVVPTSA-N ellagitannin Chemical compound OC1=C(O)C(O)=CC(C(=O)O[C@H]2C3=C4C(=O)O[C@@H]2[C@@H]2[C@@H]5OC(=O)C6=CC(O)=C(O)C(O)=C6C6=C(O)C(O)=C(O)C=C6C(=O)OC[C@H]5OC(=O)C5=CC(O)=C(O)C(O)=C5C=5C(O)=C(O)C(O)=C(C=5C(=O)O2)C4=C(O)C(O)=C3O)=C1 JMGCAHRKIVCLFW-CNWXVVPTSA-N 0.000 description 1
- 229920001968 ellagitannin Polymers 0.000 description 1
- 230000000095 emetic effect Effects 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000001050 pharmacotherapy Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
α−グルコシダーゼは、消化管での糖質の分解を触媒する酵素であり、その働きを阻害すると、糖質の分解が抑制または遅延され、糖質の吸収を抑制することができる。したがって、α−グルコシダーゼ阻害剤は食後の過血糖を顕著に抑制することから、糖尿病、肥満などの予防あるいは改善に有効である。
本発明の目的は、長期間継続的に服用しても安全かつ効果的な、α−グルコシダーゼ阻害剤を提供することにある。
【解決手段】
セキナンヨウを配合したことを特徴とするα−グルコシダーゼ阻害剤。
【選択図】 なし
Description
実施例1で得たセキナンヨウエキス(2.5% DMSOで溶解)25μl、リン酸緩衝液(0.25M、pH6.5)125μl、基質溶液50μl(1.4 mM p-nitrophenyl-α-D-glucopyranoside)、酵素溶液(Bacillus stearothermophilus由来α-Glucosidase 1.0 U/ml)50μlを添加し、37℃で30分間反応させた後、波長405 nmにおける吸光度を測定した。なお、セキナンヨウエキスは最終濃度として6.25、12.5、25、50および100μg/mLの各濃度で添加した。
実施例1で得たセキナンヨウエキスのシュークロース投与後の血糖上昇に及ぼす影響を検討した。
ob/obマウス(高血糖を発現するマウス)に実施例1で得たセキナンヨウエキスを300mg/kg(乾燥エキス換算)の用量で1日1回8週間経口投与した。最終投与日の夕方5時から絶食し、翌日にエーテル麻酔下、後大静脈から採血した。得られた血液から遠心分離法(3000rpm、20℃)により血清を分離し、試験例2に記載した方法に従って血清中のグルコース濃度(mg/dL)を定量した。
Claims (3)
- セキナンヨウを配合したことを特徴とするα−グルコシダーゼ阻害剤。
- セキナンヨウを配合したことを特徴とする糖尿病の予防または改善剤。
- セキナンヨウを配合したことを特徴とする肥満の予防または改善剤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004034321A JP4604506B2 (ja) | 2003-02-14 | 2004-02-12 | α−グルコシダーゼ阻害剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003035983 | 2003-02-14 | ||
JP2004034321A JP4604506B2 (ja) | 2003-02-14 | 2004-02-12 | α−グルコシダーゼ阻害剤 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004262930A true JP2004262930A (ja) | 2004-09-24 |
JP2004262930A5 JP2004262930A5 (ja) | 2007-03-29 |
JP4604506B2 JP4604506B2 (ja) | 2011-01-05 |
Family
ID=33133966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004034321A Expired - Fee Related JP4604506B2 (ja) | 2003-02-14 | 2004-02-12 | α−グルコシダーゼ阻害剤 |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP4604506B2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103446278A (zh) * | 2013-08-29 | 2013-12-18 | 河南大学 | 一种海棠提取物及其制备、应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001226263A (ja) * | 2000-02-17 | 2001-08-21 | Kanebo Ltd | 肥満予防剤 |
-
2004
- 2004-02-12 JP JP2004034321A patent/JP4604506B2/ja not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001226263A (ja) * | 2000-02-17 | 2001-08-21 | Kanebo Ltd | 肥満予防剤 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103446278A (zh) * | 2013-08-29 | 2013-12-18 | 河南大学 | 一种海棠提取物及其制备、应用 |
Also Published As
Publication number | Publication date |
---|---|
JP4604506B2 (ja) | 2011-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU628514B2 (en) | Inhibitive agent against activity of alpha-amylase | |
US5798101A (en) | Herbal appetite suppressant and weight loss composition | |
AU2009252911C1 (en) | Composition comprising 1, 3 /1, 6 beta glucan for reducing weight | |
JP4929611B2 (ja) | リパーゼ阻害剤 | |
KR100912243B1 (ko) | 숙취 해소용 개선제 조성물 | |
JP5609834B2 (ja) | リパーゼ阻害剤 | |
JP2017165672A (ja) | 多糖消化阻害剤 | |
JP4706174B2 (ja) | α−グルコシダーゼ阻害剤 | |
JPWO2005041995A1 (ja) | α−グルコシダーゼ活性阻害剤 | |
JP4644834B2 (ja) | ハマナス類由来のα−アミラーゼ阻害剤、α−グルコシダーゼ阻害剤、グルコース吸収阻害剤およびその利用 | |
WO2004112766A1 (en) | Composition for lowering blood glucose | |
JP4547892B2 (ja) | α−グルコシダーゼ阻害剤 | |
JP2004262930A (ja) | α−グルコシダーゼ阻害剤 | |
JP2007246478A (ja) | アセトアルデヒド代謝促進剤 | |
JP2004168767A (ja) | α−グルコシダーゼ阻害剤 | |
KR100773246B1 (ko) | 연령초 추출물을 유효성분으로 함유하는 비만 억제 및 혈당강하용 조성물 | |
JP2003226650A (ja) | 医薬用組成物 | |
JP4892833B2 (ja) | 脂肪吸収抑制剤 | |
JP4779316B2 (ja) | ジコッピ配合モノアミン再取り込み阻害剤 | |
JP4381585B2 (ja) | 医薬用組成物 | |
JP2006151838A (ja) | 糖質消化酵素阻害剤 | |
JPWO2004039388A1 (ja) | α−グルコシダーゼ阻害剤 | |
KR20040016621A (ko) | 홍차 추출물을 유효성분으로 함유하는 비만, 당뇨병,고지혈증, 지방간 및 변비 치료용 조성물 | |
JP2006016388A (ja) | αグルコシダーゼ阻害剤 | |
KR20210157343A (ko) | 요산을 감소시키기 위한 생약 조성물 및 이의 요산, 체지방, 및 혈당 감소에서의 용도 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070207 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070207 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090605 |
|
RD07 | Notification of extinguishment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7427 Effective date: 20090624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100622 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100812 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100907 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100920 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131015 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131015 Year of fee payment: 3 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |